gliosarcoma


Also found in: Dictionary, Wikipedia.
Related to gliosarcoma: glioblastoma, glioma

gliosarcoma

 [gli″o-sahr-ko´mah]
glioma combined with sarcoma.

gli·o·sar·co·ma

(glī'ō-sar-kō'mă),
A glioblastoma multiforme with an associated malignant mesenchymal component. Sometimes used as a term for a malignant neoplasm derived from connective tissue (for example, that associated with blood vessels in the brain) in which there are proliferating glial cells.

gliosarcoma

[glī′ōsärkō′mə] pl. gliosarcomas, gliosarcomata
Etymology: Gk, glia + sarx, flesh, oma, tumor
a tumor composed of spindle-shaped cells in the delicate supporting connective tissue of nerve cells. Also called glioblastoma, glioma, spongioblastoma, spongiocytoma.

gliosarcoma

Neuropathology A glioblastoma with sarcomatous elements Prognosis Poor, highly aggressive; most Pts die within 1 yr

gli·o·sar·co·ma

(glī'ō-sahr-kō'mă)
A glioblastoma multiforme with an associated malignant mesenchymal component. Sometimes used as a term for a malignant neoplasm derived from connective tissue (e.g., that associated with blood vessels in the brain) in which there are proliferating glial cells.
[G. glio, glue + sarco, flesh + -oma, tumor]
References in periodicals archive ?
Complete report on 2015 Pipeline Review of Gliosarcoma with 21 market data tables and 13 figures, spread across 62 pages is available at http://www.
List of Tables Number of Products under Development for Gliosarcoma, H1 2015 7 Number of Products under Development for Gliosarcoma - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Products under Investigation by Universities/Institutes, H1 2015 13 Gliosarcoma - Pipeline by Amgen Inc.
Gliosarcoma is a glioblastoma variant with different areas displaying glial and mesenchymal differentiation.
Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients.
Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components.
A review of the Gliosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of the Gliosarcoma pipeline on the basis of route of administration and molecule type.
Identify and understand important and diverse types of therapeutics under development for Gliosarcoma.
18) Three GBM variants are recognized as distinct clinicopathologic entities in the current WHO classification: conventional GBM, giant cell GBM (GC-GBM), and gliosarcoma (GS).
Gliosarcoma constitutes approximately 2% of GBMs and is likewise recognized as a distinct clinicopathologic entity in the WHO 2000 classification.
Additionally, the Company is planning to initiate a multi-center pivotal Phase II/III clinical trial treating individuals with glioblastoma multiforme or gliosarcoma (brain cancers) in 2007.
7(pp125,126)] Central nervous system tumors noted to arise in a field of prior irradiation include meningiomas, meningeal sarcomas, astrocytomas, primitive neuroectodermal tumors, and gliosarcomas.